@article{BertChmielewskaBergmannetal.2016,
  author    = {Bert, Bettina and Chmielewska, Justyna and Bergmann, Sven and Busch, Maximilian and Driever, Wolfgang and Finger-Baier, Karin and H{\"o}ßler, Johanna and K{\"o}hler, Almut and Leich, Nora and Misgeld, Thomas and N{\"o}ldner, Torsten and Reiher, Annegret and Schartl, Manfred and Seebach-Sproedt, Anja and Thumberger, Thomas and Sch{\"o}nfelder, Gilbert and Grune, Barbara},
  title     = {Considerations for a European animal welfare standard to evaluate adverse phenotypes in teleost fish},
  series = {The EMBO Journal},
  volume    = {35},
  journal   = {The EMBO Journal},
  number    = {11},
  doi       = {10.15252/embj.201694448},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-188783},
  pages     = {1151-1154},
  year      = {2016},
  abstract  = {No abstract available.},
  language  = {en}
}
@article{BurlinaSimsPoliteietal.2011,
  author    = {Burlina, Alessandro P. and Sims, Katherine B. and Politei, Juan M. and Bennett, Gary J. and Baron, Ralf and Sommer, Claudia and Moller, Anette Torvin and Hilz, Max J.},
  title     = {Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel},
  series = {BMC Neurology},
  volume    = {11},
  journal   = {BMC Neurology},
  number    = {61},
  doi       = {10.1186/1471-2377-11-61},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135309},
  pages     = {1-11},
  year      = {2011},
  abstract  = {Background: Fabry disease is an inherited metabolic disorder characterized by progressive lysosomal accumulation of lipids in a variety of cell types, including neural cells. Small, unmyelinated nerve fibers are particularly affected and small fiber peripheral neuropathy often clinically manifests at young age. Peripheral pain can be chronic and/or occur as provoked attacks of excruciating pain. Manifestations of dysfunction of small autonomic fibers may include, among others, impaired sweating, gastrointestinal dysmotility, and abnormal pain perception. Patients with Fabry disease often remain undiagnosed until severe complications involving the kidney, heart, peripheral nerves and/or brain have arisen. Methods: An international expert panel convened with the goal to provide guidance to clinicians who may encounter unrecognized patients with Fabry disease on how to diagnose these patients early using simple diagnostic tests. A further aim was to offer recommendations to control neuropathic pain. Results: We describe the neuropathy in Fabry disease, focusing on peripheral small fiber dysfunction - the hallmark of early neurologic involvement in this disorder. The clinical course of peripheral pain is summarized, and the importance of medical history-taking, including family history, is highlighted. A thorough physical examination (e. g., angiokeratoma, corneal opacities) and simple non-invasive sensory perception tests could provide clues to the diagnosis of Fabry disease. Reported early clinical benefits of enzyme replacement therapy include reduction of neuropathic pain, and adequate management of residual pain to a tolerable and functional level can substantially improve the quality of life for patients. Conclusions: Our recommendations can assist in diagnosing Fabry small fiber neuropathy early, and offer clinicians guidance in controlling peripheral pain. This is particularly important since management of pain in young patients with Fabry disease appears to be inadequate.},
  language  = {en}
}
@phdthesis{Geis2004,
  author    = {Geis, Christian},
  title     = {Charakterisierung von Spinalganglienneuronen intakter und l{\"a}dierter Afferenzen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-13926},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2004},
  abstract  = {Am Tiermodell einer experimentellen Mononeuropathie (chronic constriction injury, CCI) wurde bei Ratten die Expression von Zytokinen (TNF-\&\#945;, IL-10), Vanilloidrezeptor 1 (VR1) und Neuropeptiden in Spinalganglienneuronen immunhistochemisch analy-siert. Durch retrograde Anf{\"a}rbung mit den Tracern Fluorogold (FG) und Fluoruby (FR) konnten intakte von gesch{\"a}digten Neuronen unterschieden und Muskel- und Hautaffe-renzen getrennt untersucht werden. Nach CCI fand sich ein selektiver Anstieg der TNF-\&\#945; Immunreaktivit{\"a}t in mittelgroßen und großen Spinalganglienneuronen, welche durch Vergleich mit anderen neuronalen Markern als A-Faser Neurone identifiziert werden konnten. Nicht nur gesch{\"a}digte, sondern auch intakte Spinalganglienneurone wiesen eine erh{\"o}hte TNF-\&\#945; Immunreaktivit{\"a}t auf und sowohl Muskel- als auch Hautafferenzen trugen zur vermehrten TNF-\&\#945; Expression bei. IL-10, VR1 und IB4 Immunreaktivit{\"a}t fand sich vor allem in kleinen Neuronen und war nach CCI deutlich reduziert, w{\"a}hrend die Expression von CGRP in kleinen und mittel-großen Spinalganglienneuronen nachzuweisen war und keine Ver{\"a}nderung zeigte. Die Ergebnisse zeigen, dass intakt gebliebene A-Faser Neurone pathophysiologische Ver{\"a}nderungen im Sinne einer vermehrten Expression des pro-inflammatorischen Zyto-kins TNF-\&\#945; erfahren. Dieser ph{\"a}notypische Switch ist m{\"o}glicherweise mit einer neuen Funktion dieser Neurone im nozizeptiven System verbunden. Die verminderte Expression des anti-inflammatorischen Zytokins IL-10 vier Tage nach CCI korrespondiert mit der fr{\"u}hen Schmerzentstehung nach peripherer Nervenl{\"a}sion und der noch fehlenden Suppression der pro-inflammatorischen Zytokine zu diesem Zeitpunkt. Dagegen ist der R{\"u}ckgang der VR1 und IB4 Konzentrationen im Spinal-ganglion am ehesten durch einen l{\"a}sionsbedingten Mangel an neurotrophen Faktoren zu erkl{\"a}ren. Die in dieser Arbeit gewonnenen Erkenntnisse unterst{\"u}tzen die These, dass pro-inflammatorischen Zytokinen, insbesondere TNF-\&\#945;, eine besondere Bedeutung bei der Entstehung neuropathischer Schmerzen zukommt. Dies k{\"o}nnte ein Ansatzpunkt f{\"u}r wei-tere Studien sein, die Wirksamkeit TNF-\&\#945; hemmender Medikamente bei neuropathi-schen Schmerzmodellen im Tierversuch und eventuell sp{\"a}ter klinisch zu untersuchen.},
  language  = {de}
}
@article{GuckenbergerHawkinsFlentjeetal.2012,
  author    = {Guckenberger, Matthias and Hawkins, Maria and Flentje, Michael and Sweeney, Reinhart A.},
  title     = {Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-75853},
  year      = {2012},
  abstract  = {Background One third of all cancer patients will develop bone metastases and the vertebral column is involved in approximately 70 \% of these patients. Conventional radiotherapy with of 1-10 fractions and total doses of 8-30 Gy is the current standard for painful vertebral metastases; however, the median pain response is short with 3-6 months and local tumor control is limited with these rather low irradiation doses. Recent advances in radiotherapy technology - intensity modulated radiotherapy for generation of highly conformal dose distributions and image-guidance for precise treatment delivery - have made dose-escalated radiosurgery of spinal metastases possible and early results of pain and local tumor control are promising. The current study will investigate efficacy and safety of radiosurgery for painful vertebral metastases and three characteristics will distinguish this study. 1) A prognostic score for overall survival will be used for selection of patients with longer life expectancy to allow for analysis of long-term efficacy and safety. 2) Fractionated radiosurgery will be performed with the number of treatment fractions adjusted to either good (10 fractions) or intermediate (5 fractions) life expectancy. Fractionation will allow inclusion of tumors immediately abutting the spinal cord due to higher biological effective doses at the tumor - spinal cord interface compared to single fraction treatment. 3) Dose intensification will be performed in the involved parts of the vertebrae only, while uninvolved parts are treated with conventional doses using the simultaneous integrated boost concept. Methods / Design It is the study hypothesis that hypo-fractionated image-guided radiosurgery significantly improves pain relief compared to historic data of conventionally fractionated radiotherapy. Primary endpoint is pain response 3 months after radiosurgery, which is defined as pain reduction of ≥2 points at the treated vertebral site on the 0 to 10 Visual Analogue Scale. 60 patients will be included into this two-centre phase II trial. Conclusions Results of this study will refine the methods of patient selection, target volume definition, treatment planning and delivery as well as quality assurance for radiosurgery. It is the intention of this study to form the basis for a future randomized controlled trial comparing conventional radiotherapy with fractionated radiosurgery for palliation of painful vertebral metastases. Trial registration ClinicalTrials.gov Identifier: NCT01594892},
  subject      = {Medizin},
  language  = {en}
}
@phdthesis{Hochheimer2022,
  author    = {Hochheimer, Vanessa Christine},
  title     = {Of cells and enzymes: How dermal fibroblasts can impact pain in Fabry Disease and Why looking at the 3D-structure of α-Galactosidase A may be worthwhile for clinical management of Fabry patients},
  doi       = {10.25972/OPUS-29660},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-296607},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Fabry Disease (FD) is a genetic lysosomal storage disorder based on mutations in the gene encoding α-Galactosidase A (α-GalA) leading to accumulation of globotriaosylceramide (Gb3). Missense mutations induce an amino acid exchange (AAE) in the α-GalA. Pain is a predominant symptom in FD and the pathophysiology is unclear. Skin punch biopsies were obtained from 40 adult FD patients and ten healthy controls and dermal fibroblast cultures were generated for cell culture experiments to investigate Gb3 load, gene and protein expression patterns and ion channel activity. The 3D-structure of α-GalA was downloaded into Pymol Graphics System and the AAE was depicted and located in order to investigate the correlation between the AAE location type in the α-GalA and the clinical FD phenotype. FD dermal fibroblasts showed high Gb3 load depending on treatment interval and expressed Kca1.1 channels. Activity was reduced in FD cells at baseline, but increased over-proportionately upon Gb3-cleavage by enzyme replacement therapy. Gene and protein expression of Kca1.1 was increased in FD cells. FD dermal fibroblasts showed higher gene expression of Notch1 and several cytokines. Further, it was shown that three different AAE location types can be differentiated: mutations in the active site ('active site'), those buried in the core of α-GalA ('buried') and those at another location, mostly on the protein surface ('other'). FD patients carrying active site or buried mutations showed a severe clinical phenotype with multi-organ manifestation and early disease onset. Patients with other mutations were less severely affected with oligo-organ manifestation sparing the nervous system and later disease onset. These results show that dermal fibroblasts may be involved in FD-associated pain and that stratification of FD patients carrying missense mutations by AAE location type may be an advantageous parameter that can help in the management of FD patients.},
  subject      = {Fabry-Krankheit},
  language  = {en}
}
@phdthesis{Leffler2003,
  author    = {Leffler, Andreas},
  title     = {TRPV1 ist ein polymodaler Rezeptor von nozizeptiven Spinalganglienzellen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-10748},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {In der vorliegenden Arbeit wurde mittels der Whole-Cell Patch-Clamp Methode sensible Neurone von transgenen M{\"a}usen untersucht, bei denen das Gen f{\"u}r TRPV1 (transient receptor potential V1) deletiert wurde. Das Ergebniss wurde mit den Daten von Wildtyp M{\"a}usen verglichen. TRPV1 (fr{\"u}her VR1; vanilloid receptor 1) wird nahezu selektiv in sensiblen Neuronen exprimiert und wird im heterologen Expressionssystem durch Vanilloide, Hitze (> 43°C) und Protonen aktiviert. Durch diese Eigenschaften scheint TRPV1 f{\"u}r die rezeptiven Eigenschaften polymodaler Nozizeptoren von großer Bedeutung zu sein. Als ein Model des peripheren afferenten Neurons wurde die Aktivierbarkeit kultivierter Spinalganglienzellen durch Vanilloide, Protonen und Hitze elektrophysiologisch untersucht. W{\"a}hrend etwa 35\% der Wildtyp-Zellen Vanilloid-sensibel waren, fehlte in Zellen der TRPV1-knockout Maus jegliche Vanilloid-Sensibilit{\"a}t. Auch bei der Protonen-Sensibilit{\"a}t wurde eine signifikante Reduktion in TRPV1-knockout Zellen beobachtet. In Wildtyp-Zellen wurde eine hohe Protonen-Sensibilit{\"a}t fast ausschliesslich in Vanilloid-sensiblen Zellen beobachtet. Hitze-induzierte Einw{\"a}rtsstr{\"o}me mit einer Aktivierungsschwelle bei 43°C wurden ausschliesslich in Vanilloid-sensiblen Zellen der Wildtyp-Maus beobachtet. Dagegen wurden Hitze-induzierte Einw{\"a}rtsstr{\"o}me mit einer Aktivierungsschwelle {\"u}ber 53°C in sowohl Wildtyp- als auch in TRPV1-knockout Zellen beobachtet. Im Bezug auf die Bedetung von TRPV1, wurde die Funktionalit{\"a}t zwei distinkter Populationen von Spinalganglienzellen, NGF- bzw. GDNF-abh{\"a}ngigen Neuronen, durch eine Lebendf{\"a}rbung mit IB4-FITC untersucht. Hinsichtlich Vanilloid-, Protonen-, Hitze-Sensibilit{\"o}t wurden jedoch keine Unterschiede zwischen IB4-negative und IB4-positive Neuronen beobachtet. Die vorliegende Studie zeigt damit, dass TRPV1 f{\"u}r Vanilliod-Sensibilit{\"a}t sensibler Neurone essentiell ist. Weiterhin konnte gezeigt werden, dass TRPV1 ein wichtiges Transduktionselement f{\"u}r sowohl die Protonen-Sensibilit{\"a}t als auch f{\"u}r die Hitze-Sensibilit{\"a}t in Spinalganglienzellen darstellt. Die Daten dieser zellul{\"a}ren Untersuchungen konnten in weiteren in vitro und in vivo Untersuchungen best{\"a}tigt werden (Caterina et al., 2000).},
  language  = {de}
}
@article{OderVerghoErtletal.2016,
  author    = {Oder, Daniel and Vergho, Dorothee and Ertl, Georg and Wanner, Christoph and Nordbeck, Peter},
  title     = {Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles},
  series = {BMC Medical Genetics},
  volume    = {17},
  journal   = {BMC Medical Genetics},
  number    = {46},
  doi       = {10.1186/s12881-016-0309-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146617},
  year      = {2016},
  abstract  = {Background X-chromosomal inheritance patterns and generally rare occurrence of Fabry disease (FD) account for mono-mutational hemizygous male and heterozygous female patients. Female mutation carriers are usually clinically much less severely affected, which has been explained by a suggested mosaicism in cell phenotype due to random allele shutdown. However, clinical evidence is scarce and potential additional effects in female gene carriers, which might account for specific clinical characteristics such as less severe chronic kidney disease, are yet unknown. Case presentation This article reports on a 45 year old female patient carrying the two alpha-galactosidase A gene mutations c.416A > G, p.N139S in exon 3 and c.708G > C, p.W236C in exon 5, but still showing only mild organ manifestations. Conclusion This current case highlights the importance of careful clinical characterization in patients with Fabry disease, who may show additional rare constellations and, therefore, are in need of personalized medicine. The impact of potential additional protective effects exceeding the presence of a non-pathogenic GLA allele in female gene carriers requires further investigation.},
  language  = {en}
}
@article{PoliteiBouhassiraGermainetal.2016,
  author    = {Politei, Juan M. and Bouhassira, Didier and Germain, Dominique P. and Goizet, Cyril and Guerrero-Sola, Antonio and Hilz, Max J. and Hutton, Elspeth J. and Karaa, Amel and Liuori, Rocco and {\"U}ceyler, Nurcan and Zeltzer, Lonnie K. and Burlina, Alessandro},
  title     = {Pain in fabry disease: practical recommendations for diagnosis and treatment},
  series = {CNS Neuroscience \& Therapeutics},
  volume    = {22},
  journal   = {CNS Neuroscience \& Therapeutics},
  number    = {7},
  doi       = {10.1111/cns.12542},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-188127},
  pages     = {568-576},
  year      = {2016},
  abstract  = {Aims: Patients with Fabry disease (FD) characteristically develop peripheral neuropathy at an early age, with pain being a crucial symptom of underlying pathology. However, the diagnosis of pain is challenging due to the heterogeneous and nonspecific symptoms. Practical guidance on the diagnosis and management of pain in FD is needed. Methods: In 2014, experts met to discuss recent advances on this topic and update clinical guidance. Results: Emerging disease-specific tools, including FabryScan, Fabry-specific Pediatric Health and Pain Questionnaire, and Wurzburg Fabry Pain Questionnaire, and more general tools like the Total Symptom Score can aid diagnosis, characterization, and monitoring of pain in patients with FD. These tools can be complemented by more objective and quantifiable sensory testing. In male and female patients of any age, pain related to FD can be an early indication to start disease-specific enzyme replacement therapy before potentially irreversible organ damage to the kidneys, heart, or brain occurs. Conclusion: To improve treatment outcomes, pain should be diagnosed early in unrecognized or newly identified FD patients. Treatment should include: (a) enzyme replacement therapy controlling the progression of underlying pathology; (b) adjunctive, symptomatic pain management with analgesics for chronic neuropathic and acute nociceptive, and inflammatory or mixed pain; and (c) lifestyle modifications.},
  language  = {en}
}
@article{PritchardFalkLarssonetal.2016,
  author    = {Pritchard, Rory A. and Falk, Lovissa and Larsson, Mathilda and Leinders, Mathias and Sorkin, Linda S.},
  title     = {Different phosphoinositide 3-kinase isoforms mediate carrageenan nociception and inflammation},
  series = {Pain},
  volume    = {157},
  journal   = {Pain},
  number    = {1},
  doi       = {10.1097/j.pain.0000000000000341},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-191312},
  pages     = {137-146},
  year      = {2016},
  abstract  = {Phosphoinositide 3-kinases (PI3Ks) participate in signal transduction cascades that can directly activate and sensitize nociceptors and enhance pain transmission. They also play essential roles in chemotaxis and immune cell infiltration leading to inflammation. We wished to determine which PI3K isoforms were involved in each of these processes. Lightly anesthetized rats (isoflurane) were injected subcutaneously with carrageenan in their hind paws. This was preceded by a local injection of 1\% DMSO vehicle or an isoform-specific antagonist to PI3K-α (compound 15-e), -β (TGX221), -δ (Cal-101), or -γ (AS252424). We measured changes in the mechanical pain threshold and spinal c-Fos expression (4 hours after injection) as indices of nociception. Paw volume, plasma extravasation (Evans blue, 0.3 hours after injection), and neutrophil (myeloperoxidase; 1 hour after injection) and macrophage (CD11b+; 4 hour after injection) infiltration into paw tissue were the measured inflammation endpoints. Only PI3K-γ antagonist before treatment reduced the carrageenan-induced pain behavior and spinal expression of c-Fos (P <= 0.01). In contrast, pretreatment with PI3K-α, -δ, and -γ antagonists reduced early indices of inflammation. Plasma extravasation PI3K-α (P <= 0.05), -δ (P <= 0.05), and -γ (P <= 0.01), early (0-2 hour) edema -α (P <= 0.05), -δ (P <= 0.001), and -γ (P <= 0.05), and neutrophil infiltration (all P <= 0.001) were all reduced compared to vehicle pretreatment. Later (2-4 hour), edema and macrophage infiltration (P <= 0.05) were reduced by only the PI3K-δ and -γ isoform antagonists, with the PI3K-δ antagonist having a greater effect on edema. PI3K-β antagonism was ineffective in all paradigms. These data indicate that pain and clinical inflammation are pharmacologically separable and may help to explain clinical conditions in which inflammation naturally wanes or goes into remission, but pain continues unabated.},
  language  = {en}
}
@article{ReinholdSchwabeLuxetal.2018,
  author    = {Reinhold, Ann Kristin and Schwabe, Joachim and Lux, Thomas J. and Salvador, Ellaine and Rittner, Heike L.},
  title     = {Quantitative and Microstructural Changes of the Blood-Nerve Barrier in Peripheral Neuropathy},
  series = {Frontiers in Neuroscience},
  volume    = {12},
  journal   = {Frontiers in Neuroscience},
  doi       = {10.3389/fnins.2018.00936},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-225179},
  pages     = {936, 1-9},
  year      = {2018},
  abstract  = {Peripheral neuropathy is accompanied by changes in the neuronal environment. The blood-nerve barrier (BNB) is crucial in protecting the neural homeostasis: Tight junctions (TJ) seal paracellular spaces and thus prevent external stimuli from entering. In different models of neuropathic pain, the BNB is impaired, thus contributing to local damage, immune cell invasion and, ultimately, the development of neuropathy with its symptoms. In this study, we examined changes in expression and microstructural localization of two key tight junction proteins (TJP), claudin-1 and the cytoplasmic anchoring ZO-1, in the sciatic nerve of mice subjected to chronic constriction injury (CCI). Via qPCR and analysis of fluorescence immunohistochemistry, a marked downregulation of mRNA as well as decreased fluorescence intensity were observed in the nerve for both proteins. Moreover, a distinct zig-zag structure for both proteins located at cell-cell contacts, indicative of the localization of TJs, was observed in the perineurial compartment of sham-operated animals. This microstructural location in cell-cell-contacts was lost in neuropathy as semiquantified via computational analysis, based on a novel algorithm. In summary, we provide evidence that peripheral neuropathy is not only associated with decrease in relevant TJPs but also exhibits alterations in TJP arrangement and loss in barrier tightness, presumably due to internalization. Specifically, semiquantification of TJP in cell-cell-contacts of microcompartments could be used in the future for routine clinical samples of patients with neuropathy.},
  language  = {en}
}